$PFE Company News Audit: Medicare overpays for penis

New Post Public Reply Private Reply Replies (0) Message Board

Jan 17, 2014 at 11:32 AM

$PFE Company News

Audit: Medicare overpays for penis pumps 6:48 p.m. Jan. 14, 2014 - blogs.marketwatch.com
A contrarian take on the market’s correction 12:48 p.m. Jan. 9, 2014 - Mark Hulbert
Statin usefulness questioned, but patent expirations may ease pain 1:02 p.m. Jan. 8, 2014 - blogs.marketwatch.com
Cholesterol drugs: Do you need them, or not? 5:00 a.m. Jan. 8, 2014 - Elizabeth O'Brien
Buying the 2014 recovery 12:01 a.m. Jan. 7, 2014 - Jim Lowell
Dairy company Emmi acquires 50% stake in Mexideli 5:36 a.m. Jan. 3, 2014 - MarketWatch.com
10 stocks for the U.S. economy’s revival in 2014 10:14 a.m. Dec. 27, 2013 - Diana Furchtgott-Roth
Not all pharmaceuticals are created equal 12:39 p.m. Dec. 26, 2013 - The Trading Deck
Pfizer and Kaiser: They not only rhyme, they're in sync with workers 11:12 a.m. Dec. 10, 2013 - blogs.marketwatch.com
Safe and steady ETFs for the new year 12:03 p.m. Dec. 9, 2013 - Jim Lowell
Value investing for retirement portfolios 6:01 a.m. Dec. 7, 2013 - Robert Powell
Auxilium shares soar after FDA approves drug for additional use 3:53 p.m. Dec. 6, 2013 - blogs.marketwatch.com
A tale of two drug companies 4:13 p.m. Dec. 5, 2013 - Mark Hulbert
3 low-risk stocks for market skeptics 6:15 a.m. Dec. 5, 2013 - Jeff Reeves
DuPont, Pfizer are top decliners in Dow index 4:01 p.m. Dec. 3, 2013 - Polya Lesova
Large-caps can boost your portfolio at year-end 2:58 p.m. Nov. 22, 2013 - Mark Hulbert
Stock market live blog: S&P 500 record, Twitter options, China ETFs (Recap) 11:39 a.m. Nov. 18, 2013 - blogs.marketwatch.com
The best stock sector for your money now 6:01 a.m. Nov. 15, 2013 - Howard Gold
Where's the market oopmh? Cisco and a turnaround on Exxon Mobil 8:45 a.m. Nov. 13, 2013 - blogs.marketwatch.com
Bitcoin buying for dummies 3:22 p.m. Nov. 12, 2013 - blogs.marketwatch.com

Niche REITs Look Cheap 8:02 a.m. Today - Barrons.com
J&J Continues ‘Strategic Pruning’ With This Divestiture 4:08 p.m. Jan. 16, 2014 - Wall St. Cheat Sheet
AstraZeneca: Should You Buy This 4.5% Yielder? 11:56 a.m. Jan. 16, 2014 - Seeking Alpha
Drug Buyouts On The Rise -- But Buyers Changing 5:42 p.m. Jan. 15, 2014 - Investors Business Daily
Can GlaxoSmithKline Break Higher? 5:29 p.m. Jan. 15, 2014 - Wall St. Cheat Sheet
Chevron? Dividend Growth Plus Promising Projects 3:41 p.m. Jan. 15, 2014 - Seeking Alpha
Strategy Update from Merck - Analyst Blog 3:41 p.m. Jan. 15, 2014 - Zacks.com
Where to Find Yield 10:20 a.m. Jan. 15, 2014 - Barrons.com
Pfizer Inc (PFE): Today's Featured Drugs Winner 5:00 p.m. Jan. 14, 2014 - TheStreet.com
5 Stocks That Dominated the Market on Tuesday 3:20 p.m. Jan. 14, 2014 - 247WallSt.com
2 Ways To Build An All-Weather Portfolio: Timed Hedging And Sector Selection. 12:37 p.m. Jan. 14, 2014 - Seeking Alpha
A Step Back for MannKind? 11:00 a.m. Jan. 14, 2014 - Barrons.com
Jan. 14 Premarket Briefing: 10 Things You Should Know (Update 1) 8:43 a.m. Jan. 14, 2014 - TheStreet.com
Wall Street Breakfast: Must-Know News 6:33 a.m. Jan. 14, 2014 - Seeking Alpha
Pfizer's generics operations attract much interest 3:41 a.m. Jan. 14, 2014 - Seeking Alpha
Merck Becomes Latest Pharma to Consider Breakup 11:12 p.m. Jan. 13, 2014 - TheStreet.com
Can Merck Continue to Surge Higher? 5:38 p.m. Jan. 13, 2014 - Wall St. Cheat Sheet
Ligand Pharmaceuticals Poised For Full-Year Profit 4:44 p.m. Jan. 13, 2014 - Investors Business Daily
MannKind Slips on Afrezza Update - Analyst Blog 1:22 p.m. Jan. 13, 2014 - Zacks.com
Portola Pharma to continue collaboration with Bristol-Myers, Pfizer 11:02 a.m. Jan. 13, 2014 - Seeking Alpha

Statement from Pfizer Chief Medical Officer on the 50th Anniversary of the First Surgeon General's Report on Smoking and Health 10:15 a.m. Today - BusinessWire - BZX
Collaborations, Conference Participation Schedules, and Upcoming Earnings Release - Research Report on Pfizer, Humana, WellPoint, Stryker, and Centene 8:00 a.m. Jan. 14, 2014 - PR Newswire - PRF
Companies Aligned to Capitalize on New Japanese Regenerative Medicine Initiatives 10:09 a.m. Jan. 13, 2014 - ACCESSWIRE
Portola Pharmaceuticals Enters Second Clinical Collaboration Agreement With Bristol-Myers Squibb and Pfizer to Study Andexanet Alfa* (PRT4445), Investigational Factor Xa Inhibitor Reversal Agent, With Eliquis 8:00 a.m. Jan. 13, 2014 - GlobeNewswire
Avillion Group Partners with Pfizer to Co-develop BOSULIF® (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia 8:47 a.m. Jan. 9, 2014 - PR Newswire
Akili Interactive Labs Announces Partnership with Pfizer to Test Video Game in People at Risk of Alzheimer's Disease 8:03 a.m. Jan. 9, 2014 - PR Newswire
Health Care Sector Under the Lens: Pfizer, Merck & Co., AbbVie and Zogenix 8:00 a.m. Jan. 8, 2014 - PR Newswire
Nodality Enters into a Strategic Collaboration with Johnson & Johnson Innovation in Autoimmune Diseases 7:59 a.m. Jan. 8, 2014 - BusinessWire
Clinical Studies and Financial Results - Research Report on Pfizer, United Therapeutics, Insys, Puma Biotechnology, and Acorda 8:00 a.m. Jan. 1, 2014 - PR Newswire
Senesco Announces Letter of Intent to Merge with Fabrus 9:38 a.m. Dec. 30, 2013 - BusinessWire
Senesco Announces Letter of Intent to Merge with Fabrus 8:52 a.m. Dec. 30, 2013 - BusinessWire
Regulatory Submissions, New Clinical Trials, Results Scheduled, and Conference Calls - Research Report on Pfizer, Novartis, Teva, Universal Health Services, and BD 8:00 a.m. Dec. 24, 2013 - PR Newswire
Obesity Stock Plays Standing Out from the Crowd 10:04 a.m. Dec. 20, 2013 - ACCESSWIRE
Patent Settlements, Stock Price Movements, and Financial Guidance - Research Report on Pfizer, Tenet, Rockwell Medical, Magellan Health Services, and HealthSouth 8:00 a.m. Dec. 20, 2013 - PR Newswire
FDA Accepts For Review ELIQUIS(R) (apixaban) Supplemental New Drug Application for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE 5:01 p.m. Dec. 19, 2013 - BusinessWire
Athersys Confirms Completion of Patient Enrollment of Pfizer's Phase II Study of MultiStem(R) Cell Therapy for Ulcerative Colitis 7:00 a.m. Dec. 19, 2013 - GlobeNewswire
Surgical Scar Market Is Ripe for Innovation 11:15 a.m. Dec. 18, 2013 - ACCESSWIRE
Healthcare Companies Report Interim Data, Clinical Study Results, and Announcements - Research Report on Pfizer, Coronado Biosciences, Spectranetics, Celsion, and Intercept 8:00 a.m. Dec. 18, 2013 - PR Newswire
Teva Settles Viagra(R) Patent Litigation with Pfizer 4:35 p.m. Dec. 17, 2013 - BusinessWire
Pfizer Settles Viagra(R) Patent Litigation With Teva 11:55 a.m. Dec. 17, 2013 - BusinessWire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Thryfter Unleashes Livestream Magic at Goodwill Event

A Dynamic Shift in Thrift Shopping All eyes might be on Thryfter this November as they drop some serious retail knowledge at the Goodwill CONNECT Conference in Houston. We’re talking about a tech shake-up for Goodwill’s model, thanks to Thryfter's livestream shopping craze that’s poised to weld traditional thrifting with digital reach. The Power of Virtual Thrift...

CoffeeBarista.com Launches Amid High U.S. Coffee Craze

Fresh Grounds: CoffeeBarista.com Enters the Brewing Scene Alright, folks, let's cut to the chase. Digital Information Resources, the tech whiz that's been accumulating niche online properties like they're baseball cards, decided it's time to dive headfirst into the caffeinated waters with CoffeeBarista.com. Fancy name for a platform dedicated to everything bean juice,...

Soligenix Holds Steady Amidst Shifting Financial Landscape

Stepping into Soligenix's News Every time Soligenix pops up on the radar, it feels like we're watching a biopharma soap opera. This time, they're juggling updates and quarterly numbers that scream both promise and peril. The New Jersey-based company, known for its focus on niche markets with unmet medical needs, tossed out some shiny clinical developments alongside a...

Real Estate Sage: Tad Barber's Tips on Selling Your Home

Kicking Off the 2027 Home Selling Game Plan Let me tell you, the real estate world isn't for the faint-hearted. It’s a realm where a solid game plan makes a world of difference, especially when you're thinking about selling your home in 2027. In Aiken, South Carolina, it seems the local know-it-all Tad Barber has teamed up with HelloNation to throw down some insight on...

Smart City Expo 2026: Urban Solutions Take Center Stage

Urban Solutions: More Than Just Tech Buzzwords In the bustling city of Barcelona, the Smart City Expo World Congress (SCEWC) 2026 wrapped up with a throng of experts and urban innovators declaring the undeniable impact of smart city initiatives. More than just a glitzy showcase, this event was a deep dive into practical solutions for today's urban headaches like...

Freddy's Rolls Out Value Menu in Test Markets

Freddy's Value Experiment Spices Up the Fast-Food Game Wichita’s own Freddy's Frozen Custard & Steakburgers is stepping into the ring with a fresh strategy: an Everyday Value Menu. It’s quite the play, and it’s only going down in select markets. I gotta admit, the move is intriguing. These guys are taking a calculated shot, testing the waters in Arizona, Colorado,...

Alley Cat Allies Sues Lincolnton Over Cat Shooting

Legal Battle Over a Cat's Tragic End Picture the scene: a peaceful neighborhood in Lincolnton, Georgia, where the serenity was ripped apart by the shocking shooting of Piper the cat. This isn't some playground scuffle, my friends. Alley Cat Allies has taken this tragedy to the courts, filing a lawsuit against the city and its mayor. What's at stake here isn't just legal...

Research Solutions Set to Reveal Q1 FY27 Results

Understanding the Stakes Ahead of RSSS's Earnings Call Aw, the sweet suspense of earnings season. Research Solutions, Inc. (NASDAQ: RSSS) has circled November 12, 2026, as the date to let investors in on its numbers for the first quarter of fiscal year 2027. A date that's gotta have the folks over at RSSS feeling like it’s judgment day. You know how it goes—market...

Upright Proton Therapy: New Era for Cancer Care

BayCare's Bold Step into Upright Proton Therapy Here's a twist for you—BayCare Health System has rolled out something that's genuinely pushing the envelope in cancer treatment. They've treated their first patient with an upright proton therapy system. Now, talk about innovation that shakes things up. This isn't just any old upgrade; it's a complete revamp of how proton...

OncoC4's Cesalatamig: Promising Results in NSCLC Trials

Hope in Persistence: Cesalatamig in the Spotlight Swinging through the medical landscape like a seasoned fighter, OncoC4's recent revelations at the SITC 2026 give investors and doctors a reason to pay close attention. We're sizing up their investigational drug, cesalatamig, which flaunts a solid objective response rate of 33% among non-small cell lung cancer (NSCLC)...